The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure

Abhishek Chauhan; Lozan Sheriff; Mohammed T Hussain; Gwilym J Webb; Daniel A Patten; Emma Louise Shepherd; Robert K Shaw; Christopher J Weston; Debashis Haldar; Samuel Bourke; Rajan Bhandari; Stephanie Watson; David H. Adams; Steve P. Watson; Patricia F. Lalor

doi:10.1038/s41467-020-15584-3

The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure

Abhishek Chauhan^*, Lozan Sheriff, Mohammed T Hussain, Gwilym J Webb, Daniel A Patten, Emma Louise Shepherd, Robert K Shaw, Christopher J Weston, Debashis Haldar, Samuel Bourke, Rajan Bhandari, Stephanie Watson, David H. Adams, Steve P. Watson, Patricia F. Lalor

^*Corresponding author for this work

University Hospitals Birmingham , Birmingham , UK.

Research output: Contribution to journal › Article › peer-review

67 Citations (SciVal)

13 Downloads (Pure)

Abstract

Acetaminophen (APAP) is the main cause of acute liver failure in the West. Specific efficacious therapies for acute liver failure (ALF) are limited and time-dependent. The mechanisms that drive irreversible acute liver failure remain poorly characterized. Here we report that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage after toxic liver injury. Our data demonstrate that blocking platelet CLEC-2 signalling enhances liver recovery from acute toxic liver injuries (APAP and carbon tetrachloride) by increasing tumour necrosis factor-α (TNF-α) production which then enhances reparative hepatic neutrophil recruitment. We provide data from humans and mice demonstrating that platelet CLEC-2 influences the hepatic sterile inflammatory response and that this can be manipulated for therapeutic benefit in acute liver injury. Since CLEC-2 mediated platelet activation is independent of major haemostatic pathways, blocking this pathway represents a coagulopathy-sparing, specific and novel therapy in acute liver failure.

Original language	English
Article number	1939
Number of pages	12
Journal	Nature Communications
Volume	11
Issue number	1
DOIs	https://doi.org/10.1038/s41467-020-15584-3
Publication status	Published - 22 Apr 2020

Bibliographical note

Keywords

Acetaminophen/adverse effects
Animals
Blood Platelets/immunology
Carbon Tetrachloride/adverse effects
Chemical and Drug Induced Liver Injury/etiology
Humans
Lectins, C-Type/genetics
Liver/drug effects
Mice
Mice, Inbred C57BL
Neutrophils/immunology
Tumor Necrosis Factor-alpha/genetics

Access to Document

10.1038/s41467-020-15584-3Licence: CC BY 4.0

The_platelet_receptor_CLEC-2_blocks_neutrophil_mediated_hepatic_recovery_in_acetaminophen_induced_acute_liver_failure
© The Author(s) 2020 This article is licensed under a Creative Commons Attribution 4.0 International License, to view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.
Final published version, 5.08 MBLicence: CC BY 4.0

Cite this

Chauhan, A., Sheriff, L., Hussain, M. T., Webb, G. J., Patten, D. A., Shepherd, E. L., Shaw, R. K., Weston, C. J., Haldar, D., Bourke, S., Bhandari, R., Watson, S., Adams, D. H., Watson, S. P., & Lalor, P. F. (2020). The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure. Nature Communications, 11(1), Article 1939. https://doi.org/10.1038/s41467-020-15584-3

@article{992476e5ce71436da660875a9c242f0e,

title = "The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure",

abstract = "Acetaminophen (APAP) is the main cause of acute liver failure in the West. Specific efficacious therapies for acute liver failure (ALF) are limited and time-dependent. The mechanisms that drive irreversible acute liver failure remain poorly characterized. Here we report that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage after toxic liver injury. Our data demonstrate that blocking platelet CLEC-2 signalling enhances liver recovery from acute toxic liver injuries (APAP and carbon tetrachloride) by increasing tumour necrosis factor-α (TNF-α) production which then enhances reparative hepatic neutrophil recruitment. We provide data from humans and mice demonstrating that platelet CLEC-2 influences the hepatic sterile inflammatory response and that this can be manipulated for therapeutic benefit in acute liver injury. Since CLEC-2 mediated platelet activation is independent of major haemostatic pathways, blocking this pathway represents a coagulopathy-sparing, specific and novel therapy in acute liver failure.",

keywords = "Acetaminophen/adverse effects, Animals, Blood Platelets/immunology, Carbon Tetrachloride/adverse effects, Chemical and Drug Induced Liver Injury/etiology, Humans, Lectins, C-Type/genetics, Liver/drug effects, Mice, Mice, Inbred C57BL, Neutrophils/immunology, Tumor Necrosis Factor-alpha/genetics",

author = "Abhishek Chauhan and Lozan Sheriff and Hussain, {Mohammed T} and Webb, {Gwilym J} and Patten, {Daniel A} and Shepherd, {Emma Louise} and Shaw, {Robert K} and Weston, {Christopher J} and Debashis Haldar and Samuel Bourke and Rajan Bhandari and Stephanie Watson and Adams, {David H.} and Watson, {Steve P.} and Lalor, {Patricia F.}",

note = "{\textcopyright} The Author(s) 2020 This article is licensed under a Creative Commons Attribution 4.0 International License, to view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. ",

year = "2020",

month = apr,

day = "22",

doi = "10.1038/s41467-020-15584-3",

language = "English",

volume = "11",

journal = "Nature Communications",

issn = "2041-1723",

publisher = "Nature Publishing Group",

number = "1",

}

Chauhan, A, Sheriff, L, Hussain, MT, Webb, GJ, Patten, DA, Shepherd, EL, Shaw, RK, Weston, CJ, Haldar, D, Bourke, S, Bhandari, R, Watson, S, Adams, DH, Watson, SP & Lalor, PF 2020, 'The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure', Nature Communications, vol. 11, no. 1, 1939. https://doi.org/10.1038/s41467-020-15584-3

TY - JOUR

T1 - The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure

AU - Chauhan, Abhishek

AU - Sheriff, Lozan

AU - Hussain, Mohammed T

AU - Webb, Gwilym J

AU - Patten, Daniel A

AU - Shepherd, Emma Louise

AU - Shaw, Robert K

AU - Weston, Christopher J

AU - Haldar, Debashis

AU - Bourke, Samuel

AU - Bhandari, Rajan

AU - Watson, Stephanie

AU - Adams, David H.

AU - Watson, Steve P.

AU - Lalor, Patricia F.

N1 - © The Author(s) 2020 This article is licensed under a Creative Commons Attribution 4.0 International License, to view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/.

PY - 2020/4/22

Y1 - 2020/4/22

N2 - Acetaminophen (APAP) is the main cause of acute liver failure in the West. Specific efficacious therapies for acute liver failure (ALF) are limited and time-dependent. The mechanisms that drive irreversible acute liver failure remain poorly characterized. Here we report that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage after toxic liver injury. Our data demonstrate that blocking platelet CLEC-2 signalling enhances liver recovery from acute toxic liver injuries (APAP and carbon tetrachloride) by increasing tumour necrosis factor-α (TNF-α) production which then enhances reparative hepatic neutrophil recruitment. We provide data from humans and mice demonstrating that platelet CLEC-2 influences the hepatic sterile inflammatory response and that this can be manipulated for therapeutic benefit in acute liver injury. Since CLEC-2 mediated platelet activation is independent of major haemostatic pathways, blocking this pathway represents a coagulopathy-sparing, specific and novel therapy in acute liver failure.

AB - Acetaminophen (APAP) is the main cause of acute liver failure in the West. Specific efficacious therapies for acute liver failure (ALF) are limited and time-dependent. The mechanisms that drive irreversible acute liver failure remain poorly characterized. Here we report that the recently discovered platelet receptor CLEC-2 (C-type lectin-like receptor) perpetuates and worsens liver damage after toxic liver injury. Our data demonstrate that blocking platelet CLEC-2 signalling enhances liver recovery from acute toxic liver injuries (APAP and carbon tetrachloride) by increasing tumour necrosis factor-α (TNF-α) production which then enhances reparative hepatic neutrophil recruitment. We provide data from humans and mice demonstrating that platelet CLEC-2 influences the hepatic sterile inflammatory response and that this can be manipulated for therapeutic benefit in acute liver injury. Since CLEC-2 mediated platelet activation is independent of major haemostatic pathways, blocking this pathway represents a coagulopathy-sparing, specific and novel therapy in acute liver failure.

KW - Acetaminophen/adverse effects

KW - Animals

KW - Blood Platelets/immunology

KW - Carbon Tetrachloride/adverse effects

KW - Chemical and Drug Induced Liver Injury/etiology

KW - Humans

KW - Lectins, C-Type/genetics

KW - Liver/drug effects

KW - Mice

KW - Mice, Inbred C57BL

KW - Neutrophils/immunology

KW - Tumor Necrosis Factor-alpha/genetics

UR - https://www.nature.com/articles/s41467-020-15584-3#additional-information

U2 - 10.1038/s41467-020-15584-3

DO - 10.1038/s41467-020-15584-3

M3 - Article

C2 - 32321925

SN - 2041-1723

VL - 11

JO - Nature Communications

JF - Nature Communications

IS - 1

M1 - 1939

ER -

The platelet receptor CLEC-2 blocks neutrophil mediated hepatic recovery in acetaminophen induced acute liver failure

Abstract

Bibliographical note

Keywords

Access to Document

Other files and links

Fingerprint

Cite this